Trials / Terminated
TerminatedNCT03851250
A Study of MRx-4DP0004 in Asthma
A First in Human, Double-blind, Placebo-controlled, Multicentre Phase I/II Study to Evaluate the Safety, Tolerability and Immune Modulatory Effects of MRx-4DP0004 in Participants Taking Long-term Control Medication for Their Asthma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- 4D pharma plc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentre, phase I/II, double-blind, placebo-controlled study of MRx-4DP0004 in participants taking long-term medication for asthma. Participants will take two capsules of MRx-4DP0004 twice daily in addition to their existing asthma medication for 12 weeks. Safety and tolerability and immune modulatory effects of MRx-4DP0004 will be assessed throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRx-4DP0004 | Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication. |
| DRUG | Placebo | Participants randomised to receive placebo will take it in addition to their regular asthma medication. |
Timeline
- Start date
- 2019-07-04
- Primary completion
- 2023-04-26
- Completion
- 2023-04-26
- First posted
- 2019-02-22
- Last updated
- 2024-04-17
Locations
4 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03851250. Inclusion in this directory is not an endorsement.